MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

Wellington woman Amanda Broughton will have to pay $103,000 for a course of a drug, to treat her stage 3C breast cancer. The ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanc ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

Amplia Therapeutics has reported a 'complete response' from a patient with metastasised pancreatic cancer: "A rare event". ..

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.